Business

Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%

Just look at the headlines: one of the world’s largest pharmaceutical companies recently suffered three drug trial failures in a single week despite an enormous R&D budget, many talented scientists and a deep pipeline.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 22, 2026, 1:30 PM UTC
Key points
  • Business development can’t be given permission to roam the universe looking for any interesting assets; partnerships and acquisitions must reinforce the same strategy, diseases, and targets where a company believes it has a high probability of success.
  • When I joined Vertex Pharmaceuticals in 2009, the company had spent two decades investing heavily in R&D across 20 different programs.
  • If innovation is inherently unpredictable, the thinking goes, the best way to improve your chances of success is to increase the number of shots you take.

When we examined why drug development failed so frequently, the problem wasn’t that scientists had failed to create a drug that hit its intended biological target.

Additional details
  • The instinctive response when innovation fails is to do more of it: fund more projects, pursue more ideas, make more acquisitions and place more bets.
  • Companies are spending billions on R&D, acquisitions and new technologies, operating on the seemingly intuitive premise that making more bets is the best way to approach the uncertainty of the future.
  • In consumer tech, many startups flame out after a single hit; in automotive, EV pioneers are routinely outpaced by fast followers; digital investments in retail often fail to translate into customer growth.
  • Yet, it produced only a single breakthrough product, which was rendered obsolete just two and a half years later with the approval of a better and more tolerable treatment discovered by another company.
  • To break down internal silos, leaders from research, development, regulatory, manufacturing, commercial and other key business units should be included in decisions about new product development from the earliest stages of the innovation process.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet